Company’s 36-month beta value is 0.24.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RLMD is 25.39M, and currently, short sellers hold a 6.73% ratio of that floaft. The average trading volume of RLMD on April 30, 2024 was 213.38K shares.
RLMD) stock’s latest price update
Relmada Therapeutics Inc (NASDAQ: RLMD) has experienced a decline in its stock price by -7.83 compared to its previous closing price of 3.83. However, the company has seen a fall of -8.79% in its stock price over the last five trading days. PRNewsWire reported 2024-03-12 that CORAL GABLES, Fla., March 12, 2024 /PRNewswire/ — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024.
RLMD’s Market Performance
Relmada Therapeutics Inc (RLMD) has seen a -8.79% fall in stock performance for the week, with a -24.09% decline in the past month and a -5.11% plunge in the past quarter. The volatility ratio for the week is 8.49%, and the volatility levels for the past 30 days are at 7.93% for RLMD. The simple moving average for the past 20 days is -20.18% for RLMD’s stock, with a -4.29% simple moving average for the past 200 days.
Analysts’ Opinion of RLMD
Many brokerage firms have already submitted their reports for RLMD stocks, with Truist repeating the rating for RLMD by listing it as a “Hold.” The predicted price for RLMD in the upcoming period, according to Truist is $10 based on the research report published on October 14, 2022 of the previous year 2022.
Goldman gave a rating of “Neutral” to RLMD, setting the target price at $8 in the report published on October 14th of the previous year.
RLMD Trading at -31.04% from the 50-Day Moving Average
After a stumble in the market that brought RLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.12% of loss for the given period.
Volatility was left at 7.93%, however, over the last 30 days, the volatility rate increased by 8.49%, as shares sank -27.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.02% lower at present.
During the last 5 trading sessions, RLMD fell by -8.79%, which changed the moving average for the period of 200-days by +25.18% in comparison to the 20-day moving average, which settled at $4.36. In addition, Relmada Therapeutics Inc saw -14.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLMD starting from TRAVERSA SERGIO, who purchase 27,460 shares at the price of $4.00 back on Jan 31 ’24. After this action, TRAVERSA SERGIO now owns 244,024 shares of Relmada Therapeutics Inc, valued at $109,752 using the latest closing price.
Ence Chuck, the CA and CO of Relmada Therapeutics Inc, purchase 13,670 shares at $4.05 during a trade that took place back on Jan 31 ’24, which means that Ence Chuck is holding 38,970 shares at $55,429 based on the most recent closing price.
Stock Fundamentals for RLMD
The total capital return value is set at -1.21. Equity return is now at value -87.51, with -78.89 for asset returns.
Currently, EBITDA for the company is -103.7 million with net debt to EBITDA at 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.00.
Conclusion
In a nutshell, Relmada Therapeutics Inc (RLMD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
